ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) ...

ImmunityBio Investors Rally Behind Cancer Trial Milestone

ImmunityBio stock rises after 85% response rate in bladder cancer study, topping BCG alone; FDA filing planned for 2026.
Nature

Meta-analysis of BCG versus mitomycin C—a deeper insight?

Intravesical instillation with live, attenuated Mycobacterium Bacillus Calmette-Guérin (BCG) is an effective therapy for bladder cancer. Two recent analyses provide new insight into the clinical ...
Medscape

BCG Vaccination and Leprosy Protection: Review of Current Evidence and Status of BCG in Leprosy Control

There is consistent evidence that BCG protects against leprosy. However, the magnitude of such a protection varies greatly in different studies and is estimated to be approximately 41% (95% CI: 16–66% ...
Fonds

BCG : qu'est-ce que c'est

Le BCG, ou Bacille de Calmette et Guérin, est un micro-organisme dérivé du bacille tuberculeux bovin (Mycobacterium bovis). Albert Calmette, médecin et biologiste, et Camille Guérin (vétérinaire et ...